Beshay Victor E, Havelock Jon C, Sirianni Rosa, Ye Ping, Suzuki Takashi, Rainey William E, Carr Bruce R
Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, Texas 75235-9032, USA.
J Clin Endocrinol Metab. 2007 Dec;92(12):4802-9. doi: 10.1210/jc.2007-1394. Epub 2007 Sep 25.
In polycystic ovary syndrome (PCOS), there is increased formation of androgens by thecal cells. Moreover, PCOS ovaries have been shown to have decreased levels of c-fos transcription factor. We hypothesize that c-fos expression inhibits 17alpha-hydroxylase 17,20 lyase (CYP17) activity in the human ovary, and its decreased expression seen in PCOS may lead to elevated CYP17 transcription, resulting in increased androgen production.
Our objective was to define the role of the activator protein-1 transcription factors, namely c-fos, in the regulation of CYP17 expression in theca cells.
Human ovarian thecal-like tumor cells were used for all experiments. The following techniques were used: steroid quantification, mRNA extraction, microarray analysis, transfection, small interfering RNA, and immunohistochemistry.
Stimulation of human ovarian thecal-like tumor cells with the protein kinase A pathway activator forskolin resulted in stimulation of C19 androgen production. In contrast, treatment with the protein kinase C pathway activator tetradecanoylphorbol acetate (TPA) resulted in decreased androgen production with a shift toward C21 progesterone production. TPA also led to complete inhibition of CYP17. Microarray data showed a 37-fold increase in c-fos after treatment with TPA. Transfection with steroidogenic factor 1 resulted in an increase in CYP17 promoter activity, which was significantly inhibited in the presence of c-fos. c-fos gene silencing led to an increase in CYP17 mRNA levels. Immunohistochemical staining for c-fos in ovaries demonstrated strong staining in granulosa cells, but not theca.
The activator protein-1 transcription factor c-fos plays a role in the inhibition of CYP17 expression. The decreased levels of c-fos expression in polycystic ovaries may be responsible for increased CYP17 levels in PCOS.
在多囊卵巢综合征(PCOS)中,卵泡膜细胞产生的雄激素增多。此外,已表明PCOS患者的卵巢中c-fos转录因子水平降低。我们推测,c-fos表达可抑制人卵巢中17α-羟化酶17,20裂解酶(CYP17)的活性,而在PCOS中观察到的其表达降低可能导致CYP17转录升高,从而导致雄激素生成增加。
我们的目的是确定激活蛋白-1转录因子,即c-fos,在卵泡膜细胞中CYP17表达调控中的作用。
所有实验均使用人卵巢类卵泡膜肿瘤细胞。采用了以下技术:类固醇定量、mRNA提取、微阵列分析、转染、小干扰RNA和免疫组织化学。
用蛋白激酶A途径激活剂福司可林刺激人卵巢类卵泡膜肿瘤细胞可导致C19雄激素生成增加。相反,用蛋白激酶C途径激活剂十四酰佛波醇乙酸酯(TPA)处理导致雄激素生成减少,并向C21孕酮生成转变。TPA还导致CYP17完全抑制。微阵列数据显示,TPA处理后c-fos增加了37倍。用类固醇生成因子1转染导致CYP17启动子活性增加,而在存在c-fos的情况下,该活性受到显著抑制。c-fos基因沉默导致CYP17 mRNA水平升高。卵巢中c-fos的免疫组织化学染色显示,颗粒细胞中有强染色,但卵泡膜细胞中没有。
激活蛋白-1转录因子c-fos在抑制CYP17表达中起作用。多囊卵巢中c-fos表达水平降低可能是PCOS中CYP17水平升高的原因。